KHN921 / Chengdu Kanghong Pharma - LARVOL DELTA

Single-Dose AAV9-051 MYBPC3 Gene Therapy with Long-Term Assessment in Hypertrophic Cardiomyopathy (AHA 2026) - No abstract available

Gene therapy • Cardiomyopathy • Cardiovascular • Gene Therapies • Hypertrophic Cardiomyopathy

A multicenter, open-label, dose-escalation and expansion phase I/II clinical trial evaluating the tolerability, safety, and preliminary efficacy of coronary administration of KHN921 in patients with MYBPC3-mutant hypertrophic cardiomyopathy. (chinadrugtrials.org.cn) - P1 | N=18 | Not yet recruiting | Sponsor: Chengdu Hongji Biotechnology Co., Ltd.

New P1 trial • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • TNNI3